Effects of Goat Milk Formula on Gastrointestinal Comfort and Growth in Infants
A Multicenter, Randomized, Controlled Trial to Evaluate the Effects of Goat Milk Formula on Gastrointestinal Comfort, Behavioral Status, and Early Growth and Development in Infants
Infant gastrointestinal discomfort is common in early life and can affect feeding, sleep, and overall well-being. Goat milk formula, due to its unique protein composition and smaller fat globules, may be easier to digest and potentially improve gastrointestinal tolerance in infants.
This study is a multicenter, randomized, controlled trial designed to evaluate the effects of goat milk formula compared with standard cow milk formula in infants aged 0-5 months with gastrointestinal discomfort. The study will assess improvements in gastrointestinal symptoms, overall comfort, behavioral status, and early growth and development, as well as explore potential changes in gut microbiota and intestinal inflammation.
調査の概要
状態
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前：Xinqiong Wang
- 電話番号：021-64370045
- メール：wangxq1983@126.com
参加基準
適格基準
就学可能な年齢
- 子
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Infants aged 0 to 5 months at enrollment
- Full-term birth (gestational age ≥37 weeks)
- Birth weight ≥2500 g
- Infants with symptoms of gastrointestinal discomfort (e.g., abdominal distension, excessive crying, regurgitation, or feeding intolerance)
- Parents or legal guardians able and willing to provide written informed consent and comply with study procedures
Exclusion Criteria:
- Infants with known or suspected organic gastrointestinal diseases (e.g., congenital malformations, Hirschsprung disease)
- History of severe perinatal complications or significant systemic diseases
- Known or suspected cow's milk protein allergy or other food allergies
- Use of antibiotics, probiotics, or other medications that may affect gastrointestinal function within 2 weeks prior to enrollment
- Participation in another clinical study within the past 3 months
- Any condition that, in the investigator's judgment, may interfere with study participation or outcome assessment For the reference cohort: healthy breastfed infants without significant gastrointestinal symptoms
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：支持療法
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Goat Milk Formula Group
Infants in this group will be fed with goat milk-based infant formula and receive feeding and care guidance during the study period.
|
Infants will receive goat milk-based formula as their primary feeding during the intervention period, according to standard feeding practices.
|
|
アクティブコンパレータ：Cow Milk Formula Group
Infants in this group will continue to receive standard cow milk-based infant formula and receive feeding and care guidance during the study period.
|
Infants will receive standard cow milk-based formula as their primary feeding during the intervention period, according to routine feeding practices.
|
|
介入なし：Healthy breastfeeding
No feeding intervention will be performed; only fecal samples and clinical data will be collected.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Response Rate Based on Infant Composite Comfort Score (ICCS) at Day 14
時間枠：Baseline to Day 14
|
The overall response rate is defined as the proportion of participants in each group showing a ≥30% improvement in ICCS from baseline to Day 14. ICCS is a composite measure combining gastrointestinal symptom burden and behavioral state, with total scores ranging from 0 to 30.
Higher scores indicate better overall comfort (better outcome).
Response is categorized as: Markedly Effective (improvement ≥50%), Effective (improvement ≥30% to <50%), and Ineffective (improvement <30% or worsening).
The overall response rate is calculated as (Markedly Effective + Effective) / Total Cases × 100%.
|
Baseline to Day 14
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Gastrointestinal Symptom Burden Score
時間枠：Baseline to Day 28
|
Change in gastrointestinal symptom burden score from baseline to Day 28, assessed using the Infant Gastrointestinal Symptom Assessment Scale.
The scale ranges from 0 to 15, with higher scores indicating greater symptom burden (worse outcome).
|
Baseline to Day 28
|
|
Resolution Rate of Individual Gastrointestinal Symptoms
時間枠：Day 28
|
Proportion of infants with complete resolution of individual gastrointestinal symptoms (e.g., abdominal distension, crying, vomiting) by Day 28.
|
Day 28
|
|
Change in Daily Sleep Duration
時間枠：Baseline to Day 28
|
Change in total daily sleep duration (minutes) based on caregiver-recorded 24-hour infant behavior diary.
|
Baseline to Day 28
|
|
Change in Daily Awake and Content Time
時間枠：Baseline to Day 28
|
Change in total daily duration of awake and content state as reported by caregivers.
|
Baseline to Day 28
|
|
Change in Parent-Reported Infant Comfort/Feeding Experience
時間枠：Baseline to Day 28
|
Change from baseline to Day 28 in parent-reported infant comfort experience, assessed using the following instrument: Parenting Feeding and Nurturing Experience Questionnaire total score. This questionnaire consists of 5 items, each scored from 1 to 5, giving a total score range of 5 to 25. Higher scores indicate a more positive parenting and feeding experience (better outcome). |
Baseline to Day 28
|
|
Change in Parent-Reported Infant Feeding Experience
時間枠：Baseline to Day 28
|
Change from baseline to Day 28 in parent-reported infant feeding experience, assessed using the following instrument: Visual Analogue Scale (VAS) scores for parent-perceived infant overall comfort, feeding smoothness, and maternal anxiety. Each VAS item ranges from 0 to 10. For all three items, higher scores indicate better outcomes (i.e., more comfort, smoother feeding, and less anxiety). |
Baseline to Day 28
|
|
Change in Weight-for-Age Z-Score
時間枠：Baseline to Day 28
|
Change in weight-for-age Z-score from baseline to Day 28.
Weight is measured in kilograms (kg) using a calibrated electronic infant scale.
The Z-score is a continuous variable (standard deviation units relative to the WHO child growth standard), with a typical clinical range of -3 to +3.
Higher Z-scores indicate greater weight for age, generally reflecting better growth outcomes in this population.
|
Baseline to Day 28
|
|
Change in Head Circumference-for-Age Z-Score
時間枠：Baseline to Day 28
|
Change in head circumference-for-age Z-score from baseline to Day 28.
Head circumference is measured in centimeters (cm) using a non-stretchable measuring tape.
The Z-score is a continuous variable (standard deviation units relative to the WHO child growth standard), with a typical clinical range of -3 to +3.
Higher Z-scores indicate greater head circumference for age, reflecting appropriate brain and cranial growth.
|
Baseline to Day 28
|
|
Change in Length-for-Age Z-Score
時間枠：Baseline to Day 28
|
Change in length-for-age Z-score from baseline to Day 28.
Length is measured in centimeters (cm) using a standard infant length measurement board.
The Z-score is a continuous variable (standard deviation units relative to the WHO child growth standard), with a typical clinical range of -3 to +3.
Higher Z-scores indicate greater length for age, generally reflecting better growth outcomes in this population.
|
Baseline to Day 28
|
|
Changes in Gut Microbiota Composition
時間枠：Baseline and Week 4
|
Changes in gut microbiota composition, including relative abundance of key bacterial taxa, assessed by 16S rRNA sequencing of stool samples.
|
Baseline and Week 4
|
|
Change in Fecal Calprotectin Levels
時間枠：Baseline and Week 4
|
Change in fecal calprotectin concentration as a marker of intestinal inflammation.
|
Baseline and Week 4
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。